Prescribing preferences and personal experience of female gynaecologists in Germany and Austria regarding use of extended-cycle oral contraceptives

Inka Wiegratz; Katrin Galiläer; Nicole Sänger; Achim Rody; Herbert Kühl; Herbert Kuhl; E Schleußner; Ekkehard Schleussner

doi:10.3109/13625187.2010.518708

Prescribing preferences and personal experience of female gynaecologists in Germany and Austria regarding use of extended-cycle oral contraceptives

Inka Wiegratz, Katrin Galiläer, Nicole Sänger, Achim Rody, Herbert Kühl, Herbert Kuhl, E Schleußner, Ekkehard Schleussner

The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception · 2010 · vol. 15(6) , pp. 405–412 · doi:10.3109/13625187.2010.518708 · PMID:20863264 · W2020094257

Observational OA: closed CC0

View on OpenAlex View on PubMed View at publisher

⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-11 ⓘ

German and Austrian female gynecologists widely prescribe and personally use extended-cycle oral contraceptives for medical reasons, regardless of their own extended-cycle use experience.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVES: To investigate prescribing preferences and personal experience of female gynaecologists with extended-cycle use of combined oral contraceptives (COCs) in Germany and Austria. METHODS: A questionnaire on prescribing patterns and personal experience with extended COC regimens was delivered to female gynaecologists practising in Germany and Austria. RESULTS: Of 2,500 delivered questionnaires, 1,113 were returned. After exclusion of 22 invalid questionnaires, the remaining 1,091 (43.6% of delivered questionnaires) remained eligible for analysis and were considered as the full analysis set (100%). Nearly all gynaecologists (97%) reported prescription of extended-cycle regimens to their patients, independent of their personal experience as users. The main medical reasons for prescription were cycle-related headache (93.8%), dysmenorrhoea (88.2%), cycle-related complaints (74.5%), and hypermenorrhoea (70.9%). In total, 863 gynaecologists had personally used COCs, 321 (37.2%) in extended-cycle regimen. The most commonly employed combinations were 30 μg ethinylestradiol (EE) + 2 mg dienogest (n = 114; 37.5%) and 30 μg EE + 3 mg drospirenone (n = 69; 22.7%). CONCLUSIONS: Although considered off-label use, extended-cycle use of COCs is widely prescribed and personally used by German and Austrian female gynaecologists. The lack of personal experience with extended-cycle use does not impair the prescribing habit of gynaecologists with regard to extended-cycle regimens.

My notes (saved in your browser only)

Condition tags

dysmenorrhea

MeSH descriptors

Contraceptives, Oral, Combined Gynecology Off-Label Use Practice Patterns, Physicians' Austria Drug Administration Schedule Female Germany Gynecology Health Care Surveys Humans Practice Patterns, Physicians' Surveys and Questionnaires

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (25)

Effects of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg dienogest on lipid metabolism during 1 year of conventional or extended-cycle use via openalex
Effects of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg dienogest on thyroid hormones and androgen parameters: conventional vs. extended-cycle use via openalex
Effects of conventional or extended-cycle regimen of an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on various hemostasis parameters via openalex
Extended and continuous use of hormonal contraceptives to reduce menstruation via openalex
Non-contraceptive health benefits of oral contraceptives via openalex
doi:10.1016/j.ajog.2004.02.012 via openalex
doi:10.1016/s0029-7844(03)00014-0 via openalex
doi:10.1016/s0029-7844(99)00524-4 via openalex
doi:10.1016/j.jadohealth.2006.09.013 via openalex
doi:10.1016/j.contraception.2009.05.004 via openalex
doi:10.1016/j.contraception.2005.07.001 via openalex
doi:10.1016/s0010-7824(03)00141-0 via openalex
doi:10.1016/j.contraception.2007.02.005 via openalex
doi:10.1016/j.contraception.2003.09.004 via openalex
doi:10.1055/s-0030-1248263 via openalex
doi:10.1016/j.contraception.2006.07.005 via openalex
doi:10.1016/j.contraception.2004.06.008 via openalex
doi:10.1016/0010-7824(90)90050-6 via openalex
doi:10.2165/00003495-200464210-00006 via openalex
doi:10.1016/j.ajog.2006.02.048 via openalex
doi:10.1016/j.contraception.2005.09.009 via openalex
doi:10.1016/j.contraception.2010.06.015 via openalex
doi:10.1358/dot.2008.44.3.1197950 via openalex
doi:10.1080/13625180701800672 via openalex
doi:10.1016/j.contraception.2007.01.014 via openalex

Source provenance

openalex: last seen: 2026-05-11T06:40:38.933960+00:00
pubmed: last seen: 2026-10-08T21:08:04.945943+00:00
unpaywall: last seen: 2026-11-11T07:04:17.060302+00:00

License: CC0 · commercial use OK

[1] Effects of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg dienogest on lipid metabolism during 1 year of conventional or extended-cycle use via openalex

[2] Effects of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg dienogest on thyroid hormones and androgen parameters: conventional vs. extended-cycle use via openalex

[3] Effects of conventional or extended-cycle regimen of an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on various hemostasis parameters via openalex

[4] Extended and continuous use of hormonal contraceptives to reduce menstruation via openalex

[5] Non-contraceptive health benefits of oral contraceptives via openalex

[6] doi:10.1016/j.ajog.2004.02.012 via openalex

[7] doi:10.1016/s0029-7844(03)00014-0 via openalex

[8] doi:10.1016/s0029-7844(99)00524-4 via openalex

[9] doi:10.1016/j.jadohealth.2006.09.013 via openalex

[10] doi:10.1016/j.contraception.2009.05.004 via openalex

[11] doi:10.1016/j.contraception.2005.07.001 via openalex

[12] doi:10.1016/s0010-7824(03)00141-0 via openalex

[13] doi:10.1016/j.contraception.2007.02.005 via openalex

[14] doi:10.1016/j.contraception.2003.09.004 via openalex

[15] doi:10.1055/s-0030-1248263 via openalex

[16] doi:10.1016/j.contraception.2006.07.005 via openalex

[17] doi:10.1016/j.contraception.2004.06.008 via openalex

[18] doi:10.1016/0010-7824(90)90050-6 via openalex

[19] doi:10.2165/00003495-200464210-00006 via openalex

[20] doi:10.1016/j.ajog.2006.02.048 via openalex

[21] doi:10.1016/j.contraception.2005.09.009 via openalex

[22] doi:10.1016/j.contraception.2010.06.015 via openalex

[23] doi:10.1358/dot.2008.44.3.1197950 via openalex

[24] doi:10.1080/13625180701800672 via openalex

[25] doi:10.1016/j.contraception.2007.01.014 via openalex